SOUTH AFRICA'S ENALENI PLANS TO SUE LUPIN

South Africa's largest generic drug company Enaleni Pharmaceuticals is planning to sue Lupin the Rs 1,200 crore domestic pharma major for terminating a marketing right unilaterally in violation of an existing agreement. The Durban-based Enaleni is now all set to drag the Indian company to court on behalf of Specpharm and Westbury companies recently acquired by Enaleni. Specpharm and Westbury had a four-year agreement, which was signed in June 2002, to distribute Lupin's anti-TB drugs in South Africa and other African markets.

Sify (http://sify.com/finance/equity/fullstory.php?id=13966876)